Showing 2051-2060 of 19309 results for "".
Improving Diagnosis of Castleman Disease: The Key Role of Stromal Cells
https://reachmd.com/programs/project-oncology/improving-diagnosis-of-castleman-disease-the-key-role-of-stromal-cells/26400/Discover how stromal cells can inform new diagnostic methods and therapeutic strategies for Castleman disease.Mental Health Implications in Psoriasis
https://reachmd.com/programs/practical-dermatology-il-17-journal-club/mental-health-implications-in-psoriasis/48771/Andrew Blauvelt, MD, MBA, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to talk about how IL-17 inhibition can reduce suicidal ideation and behavior in psoriasis patients, as covered in the Journal of the American Academy of Dermatology article “Mental health outcomes in paUnderstanding the Effect of Targeting IL-17A/F in Psoriatic Arthritis
https://reachmd.com/programs/practical-dermatology-il-17-journal-club/understanding-the-effect-of-targeting-il-17af-in-psoriatic-arthritis/56663/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, and Naeim T. Issa, MD, PhD, FAAD, continue their discussion of the Mediterranean Journal of Rheumatology article “Emerging Targets in Psoriatic Arthritis: Dual IL-17A/F and Selective TYK2 Inhibition in a Clinical Perspective,” focusinHow Timing, Titration Speed, and Antiseizure Medication Burden Influence VNS Therapy Outcomes in Epilepsy
https://reachmd.com/programs/practical-neurology/how-timing-titration-speed-and-antiseizure-medication-burden-influence-vns-therapy-outcomes-in-epilepsy/39917/Ryan Verner, PhD, discusses findings from the large, global CORE-VNS study, including how earlier vagus nerve stimulation use and lower baseline antiseizure medication burden were associated with improved clinical response.Immune Checkpoint Inhibitors Show Promise in Patients with Oncogene Driver-Negative NSCLC Who Have Never Smoked
https://reachmd.com/programs/project-oncology/immune-checkpoint-inhibitors-show-promise-in-patients-with-oncogene-driver-negative-nsclc-who-have-never-smoked/33000/A multi-institutional study presented at ASCO 2025 offers critical new insights into a long-overlooked subset of non-small cell lung cancer (NSCLC) patients: never-smokers without actionable oncogenic drivers. Read about the study’s findings on the key predictors of response to immune checkpoint inhIVUS Trial
https://reachmd.com/programs/clinicians-roundtable/ivus-trial/600/Overview of the IVUS trial and resultsShared Financial Incentives for Both Physicians and Patients Improved Cholesterol Levels
https://reachmd.com/programs/the-jama-report/shared-financial-incentives-both-physicians-and-patients-improved-cholesterol-levels/7744/[Read the Article] Financial incentives for physicians or patients are one way healthcare organizations are trying to improve health outcomes. A new study examined whether providing these financial incentives would help improve low-density lipoprotein cholesterol (LDL-C) in patients with a high-riskPrimary Biliary Cholangitis Pathophysiology: From Genetic Risk to Immune Dysregulation
https://reachmd.com/programs/gi-insights/primary-biliary-cholangitis-pathophysiology-from-genetic-risk-to-immune-dysregulation/29159/Tune in to find out how genetic and environmental triggers can cause immune dysregulation in primary biliary cholangitis.Informed Consent
https://reachmd.com/programs/clinicians-roundtable/informed-consent-1/844/Dr. Michael Greenberg welcomes Dr. James Gottesman as he discusses how using a computer generated consent and information forms can help reduce physician stress.Informed Consent
https://reachmd.com/programs/clinicians-roundtable/informed-consent/843/In this segment, Dr. Michael Greenberg speaks with Dr. James Gottesman about how a more extensive informed consent can save doctors time and money